Workshop II: "neuroprotection"--the Lugano consensus.
Standard
Workshop II: "neuroprotection"--the Lugano consensus. / Riederer, P; Brücke, T; Buhmann, Carsten; Müller, T; Schwartz, A; Storch, A; Winner, B.
in: J NEUROL, Jahrgang 247, Nr. 4, 4, 2000, S. 36-37.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Workshop II: "neuroprotection"--the Lugano consensus.
AU - Riederer, P
AU - Brücke, T
AU - Buhmann, Carsten
AU - Müller, T
AU - Schwartz, A
AU - Storch, A
AU - Winner, B
PY - 2000
Y1 - 2000
N2 - Consensus could be reached that there is overwhelming evidence of preclinical neuroprotection. However, the evidence of neuroprotection/neurorescue under clinical conditions is limited. Lessons from clinical trials designed to show neuroprotection (selegiline, amantadine, dopamine agonists) demonstrate that with the drugs available neuroprotection/neurorescue has to start as early as possible. A PET-controlled clinical trial with ropinirole shows that there seems to be a good chance for neuroprotection in the early phase of Parkinson's disease in patients treated from the very beginning of the disease while there is no such benefit in patients with a late start of a neuroprotective therapeutic strategy. Also long-term neuroprotection cannot be reached. Complicating factors to demonstrate clinical neuroprotection are discussed.
AB - Consensus could be reached that there is overwhelming evidence of preclinical neuroprotection. However, the evidence of neuroprotection/neurorescue under clinical conditions is limited. Lessons from clinical trials designed to show neuroprotection (selegiline, amantadine, dopamine agonists) demonstrate that with the drugs available neuroprotection/neurorescue has to start as early as possible. A PET-controlled clinical trial with ropinirole shows that there seems to be a good chance for neuroprotection in the early phase of Parkinson's disease in patients treated from the very beginning of the disease while there is no such benefit in patients with a late start of a neuroprotective therapeutic strategy. Also long-term neuroprotection cannot be reached. Complicating factors to demonstrate clinical neuroprotection are discussed.
M3 - SCORING: Zeitschriftenaufsatz
VL - 247
SP - 36
EP - 37
JO - J NEUROL
JF - J NEUROL
SN - 0340-5354
IS - 4
M1 - 4
ER -
